Alliance Pharma PLC (LON:APH) expects trading this year will be weighted toward the second half and be dependent upon the speed of Asia’s recover from the coronavirus pandemic.

In a brief update, accompanying confirmation of a delay to publication of its full-year results, the drugs group said demand in the Asia Pacific region, including China, will be lower in the first half of 2020 but is expected to pick up thereafter.

Sales in the UK and Europe will be less by the virus affected due to a higher proportion of prescription medicines sold in this region, it added.

The supply chain is also holding up well, Alliance said, while for products sold directly it holds a minimum of 3 months of inventory or more.  Most international sales are generated via distributors, who also typically hold 3-6 months of inventory, the group added.

Results for 2019 were scheduled to be released tomorrow with the audit essentially complete but following the FCA’s guidelines, they have been postponed until the regulatory moratorium has been lifted, Alliance noted.